Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
Study sponsor: PDS Biotechnology Corp. · PDSB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-05-14Actual
Enrollment · participants95Actual
Source updated2025-10-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.